Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 5:33 pm Purchase | 2025-03-31 | 13G | Avalo Therapeutics, Inc. AVTX | Ikarian Capital, LLC | 1,191,957 9.990% | 221,598 (+22.84%) | Filing History |
| 2025-05-15 5:26 pm Purchase | 2025-03-31 | 13G | Traws Pharma, Inc. TRAW | Ikarian Capital, LLC | 589,502 9.990% | 195,247 (+49.52%) | Filing History |
| 2025-05-15 5:26 pm Purchase | 2025-03-31 | 13G | Cumberland Pharmaceuticals Inc. CPIX | Ikarian Capital, LLC | 730,932 4.900% | 730,932 (New Position) | Filing History |
| 2025-02-14 1:25 pm Purchase | 2024-12-31 | 13G | Avenue Therapeutics, Inc. ATXI | Ikarian Capital, LLC | 140,000 6.800% | 140,000 (New Position) | Filing History |
| 2025-02-14 1:22 pm Purchase | 2024-12-31 | 13G | Galera Therapeutics, Inc. GRTX | Ikarian Capital, LLC | 7,538,690 9.990% | 7,538,690 (New Position) | Filing History |
| 2025-02-14 1:21 pm Purchase | 2024-12-31 | 13G | Aethlon Medical, Inc. AEMD | Ikarian Capital, LLC | 1,229,285 8.700% | 1,229,285 (New Position) | Filing History |
| 2025-02-14 1:18 pm Purchase | 2024-12-31 | 13G | Traws Pharma, Inc. TRAW | Ikarian Capital, LLC | 394,255 9.990% | 394,255 (New Position) | Filing History |
| 2025-02-14 1:15 pm Purchase | 2024-12-31 | 13G | Forte Biosciences, Inc. FBRX | Ikarian Capital, LLC | 609,225 9.500% | 609,225 (New Position) | Filing History |
| 2025-02-14 1:09 pm Purchase | 2024-12-31 | 13G | Channel Therapeutics Corporation CHRO | Ikarian Capital, LLC | 440,849 7.300% | 440,849 (New Position) | Filing History |
| 2025-02-14 1:07 pm Purchase | 2024-12-31 | 13G | Alpha Cognition Inc. Common Stock ACOG | Ikarian Capital, LLC | 967,867 6.000% | 967,867 (New Position) | Filing History |
| 2024-11-14 8:51 pm Purchase | 2024-09-30 | 13G | TRACON Pharmaceuticals, Inc. TCON | Ikarian Capital, LLC | 133,404 3.900% | 133,404 (New Position) | Filing History |
| 2024-11-14 8:47 pm Purchase | 2024-09-30 | 13G | iBio, Inc. IBIO | Ikarian Capital, LLC | 599,913 6.600% | 599,913 (New Position) | Filing History |
| 2024-10-07 8:06 pm Purchase | 2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Ikarian Capital, LLC | 970,359 10.020% | 970,359 (New Position) | Filing History |
| 2024-04-05 4:10 pm Purchase | 2024-03-31 | 13G | TRACON Pharmaceuticals, Inc. TCON | Ikarian Capital, LLC | 133,547 5.900% | 133,547 (New Position) | Filing History |
| 2024-02-14 6:00 pm Unchanged | 2023-12-31 | 13G | Bellicum Pharmaceuticals, Inc. BLCM | Ikarian Capital, LLC | 448,101 4.600% | 0 (Unchanged) | Filing History |
| 2023-02-14 12:57 pm Purchase | 2022-12-31 | 13G | TRACON Pharmaceuticals, Inc. TCON | Ikarian Capital, LLC | 138,277 12.500% | 3,721 (+2.77%) | Filing History |
| 2023-02-14 11:26 am Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Ikarian Capital, LLC | 11,638 0.300% | -63,845 (-84.58%) | Filing History |
| 2023-02-14 11:03 am Sale | 2022-12-31 | 13G | Milestone Pharmaceuticals Inc. MIST | Ikarian Capital, LLC | 460,416 1.300% | -1,289,627 (-73.69%) | Filing History |
| 2023-02-14 11:02 am Sale | 2022-12-31 | 13G | Bellicum Pharmaceuticals, Inc. BLCM | Ikarian Capital, LLC | 448,101 5.200% | -48,655 (-9.79%) | Filing History |
| 2022-02-14 4:43 pm Sale | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Ikarian Capital, LLC | 75,483 8.100% | -12,017 (-13.73%) | Filing History |